Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Bryhali is a prescription topical corticosteroid containing halobetasol propionate 0.01%. It is approved for plaque psoriasis in adults. Each gram contains 0.1 mg of halobetasol propionate. The lotion is applied to affected skin once daily, and treatment beyond eight weeks is not recommended. Pediatric safety and efficacy have not been established.
read more about bryhali ...Halobetasol propionate is a synthetic corticosteroid with potent glucocorticoid activity. Corticosteroids affect cellular signaling, immune function, inflammation, and protein regulation. The precise mechanism responsible for Bryhali treatment effects in plaque psoriasis is unknown. Its topical corticosteroid activity reduces inflammatory responses in treated skin.
Bryhali is approved for topical treatment of plaque psoriasis in adults. Safety and efficacy in patients younger than 18 have not been established. The lotion is for skin use only and is not intended for oral, ophthalmic, or intravaginal use.
A thin layer of Bryhali is applied to affected areas once daily and rubbed in gently. Treatment stops when psoriasis is controlled and should not continue beyond eight weeks. Total use should not exceed about 50 g per week. The lotion is avoided on the face, groin, and armpits and is not used under occlusive dressings unless directed.
Bryhali can suppress the hypothalamic-pituitary-adrenal axis and is linked to Cushing syndrome, high blood glucose, glucose in the urine, skin atrophy, stretch marks, visible small blood vessels, pigment changes, and allergic contact dermatitis. Topical corticosteroids are also linked to cataracts and glaucoma. Larger treatment areas, prolonged use, occlusion, or damaged skin increase systemic exposure.
Bryhali treats plaque psoriasis in adults.
A thin layer is applied to affected skin once daily and rubbed in gently.
Current labeling states that treatment beyond eight weeks is not recommended and treatment stops earlier when psoriasis is controlled.
No. Current prescribing information directs patients to avoid use on the face, groin, or armpits.
BRYHALI (halobetasol propionate) Lotion Prescribing Information. https://pi.bauschhealth.com/globalassets/BHC/PI/Bryhali-PI.pdf. Date Accessed September 17, 2026.
DailyMed - BRYHALI (halobetasol propionate) lotion. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4bbb66a-3f9d-4091-b1b0-1cbc908432d3. Date Accessed September 17, 2026.
Halobetasol Propionate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/6918178. Date Accessed September 17, 2026.
Halobetasol Topical. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a601060.html. Date Accessed September 17, 2026.
NDA/BLA Multi-disciplinary Review and Evaluation - NDA 209355 BRYHALI (halobetasol propionate) Lotion, 0.01%. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209355Orig1s000MultidisciplineR.pdf. Date Accessed September 17, 2026.